We still have no clear or convincing explanation as to why AstraZeneca won't deliver doses from its UK facilities to the EU, in addition to the Belgium and NL ones, as allowed for in the contract.

Yep, that is a crucial bit of missing information. Also, are there any penalties for non-delivery in the contract?

And does EU have any equivalent to the US War Production Act to set aside the Oxford/AztraZeneca patent rights and let production companies churn out generica as soon as possible?

By happenstance I found out that Finland is using doses made in Sweden (in Södertälje to be precise).